April 18, 2025

FDA Approves New Spontaneous Urticaria Therapy

The FDA approved dupilumab as the first targeted therapy for chronic spontaneous urticaria in patients aged 12 years and older uncontrolled on antihistamines.

Conexiant

April 16, 2025

CONSORT 2025: Setting New Standards for Clinical Trial Reporting

"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.

Conexiant

April 15, 2025

Preferred Lip Size Differs by Gender

"Lip plumping will mostly appeal to women rather than men (who prefer thinner lips)," finds new research showing how lip size manipulations influence perceived facial attractiveness.

Conexiant

April 15, 2025

Can Exclusive Breastfeeding Lower Atopic Dermatitis Risk?

An invited commentary in JAAD reviewed current evidence indicating that exclusive breastfeeding for the first 3 to 4 months decreases cumulative incidence of atopic dermatitis in the first 2 years of life.

Conexiant

April 11, 2025

Early Antibiotics Linked to Asthma, Eczema

Researchers found early-life antibiotic use was linked to increased risk of asthma and eczema, but not most other immune diseases, after adjusting for familial factors.

Conexiant

April 09, 2025

Port Wine Stains Respond to Laser

595-nm pulsed dye laser treatment in infants was associated with mild, well-tolerated adverse effects.

Conexiant

April 08, 2025

Burn Scar Study Shows Laser Benefits

Fractional CO₂ laser therapy improves vascularity, pigmentation, and pliability in hypertrophic burn scars among patients with skin of color.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 27, 2025

Trends in Spironolactone Prescribing Among Young Women

A cohort study of 38 million insured females aged 12 to 40 years found a marked increase in spironolactone prescriptions, most commonly for acne and other androgen-related conditions.

Conexiant